No Data
No Data
No Data
Lobe Sciences Ltd. and Clearway Global Announce Change of Control and Focus on Creating Value for Shareholders
Lobe Sciences Ltd. ("Lobe" or the "Company") (OTCQB: LOBEF) (CSE: LOBE), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases and Clearway Global, LLC ("Clearway"), a wholly owned subsidiary of Sancilio & Company ("Sancilio"), a pharmaceutical services company focused on value creation strategies, are pleased to announce a change in control of the Company and several enhancements to its ongoing growth strategy.
Lobe Sciences Announces Change of Control | CSE:LOBE, OTCQB:LOBEF
Lobe Sciences Provides Company Review of 2023
Lobe Sciences Provides Update on L-130 Clinical Program
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound
Biopharmaceutical company Lobe Sciences Ltd. (LOBE.CSE), on Tuesday announced its lead clinical asset, L-130, a proprietary stabilized psilocin conjugate drug candidate, recently surpassed the 12-mon
Lobe Sciences Appoints CFO
Lobe Sciences Ltd. (LOBE.CSE) said Monday that it has named Mathew Lee chief financial officer of the company. Lee currently serves as president of Manning Lee Management Ltd., a management consulting